A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 15.1B | 15.1B | 15.5B | 14.9B | 15.1B |
| Net Income | 1.5B | 1.5B | 1.0B | 2.1B | 2.1B |
| EPS | $0.76 | $0.76 | $0.54 | $1.20 | $1.21 |
| Free Cash Flow | 1.7B | 1.7B | 1.3B | 2.1B | 39M |
| ROIC | 9.0% | 9.8% | 7.6% | 12.1% | - |
| Gross Margin | 58.1% | 58.1% | 58.0% | 55.4% | 55.9% |
| Debt/Equity | 0.93 | 0.93 | 1.05 | 0.79 | - |
| Dividends/Share | $0.82 | $0.83 | $0.81 | $0.45 | $0.00 |
| Operating Income | 2.4B | 2.4B | 1.8B | 2.7B | 2.9B |
| Operating Margin | 16.0% | 16.0% | 11.9% | 17.9% | 19.4% |
| ROE | 13.7% | 14.4% | 10.7% | 18.4% | - |
| Shares Outstanding | 1,934M | 1,934M | 1,907M | 1,720M | 1,717M |
| Metric | 2022 | 2023 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 15.1B | 14.9B | 15.5B | 15.1B | 15.1B |
| Gross Margin | 55.9% | 55.4% | 58.0% | 58.1% | 58.1% |
| R&D | 355M | 399M | 408M | 382M | 382M |
| SG&A | 5.5B | 5.6B | 6.3B | 6.1B | 6.1B |
| EBIT | 2.9B | 2.7B | 1.8B | 2.4B | 2.4B |
| Op. Margin | 19.4% | 17.9% | 11.9% | 16.0% | 16.0% |
| Net Income | 2.1B | 2.1B | 1.0B | 1.5B | 1.5B |
| Net Margin | 13.8% | 13.8% | 6.7% | 9.7% | 9.7% |
| Non-Recurring | 117M | 12M | 763M | 313M | 313M |
| Returns on Capital | |||||
| ROIC | N/A | 12.1% | 7.6% | 9.8% | 9.0% |
| ROE | N/A | 18.4% | 10.7% | 14.4% | 13.7% |
| ROA | N/A | 7.4% | 4.0% | 5.6% | 5.4% |
| Cash Flow | |||||
| Op. Cash Flow | 334M | 2.5B | 1.8B | 2.2B | 2.2B |
| Free Cash Flow | 39M | 2.1B | 1.3B | 1.7B | 1.7B |
| Owner Earnings | -538M | 1.7B | 893M | 1.5B | 1.5B |
| CapEx | 295M | 375M | 434M | 475M | 475M |
| Maint. CapEx | 731M | 644M | 622M | 557M | 557M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 |
| D&A | 731M | 644M | 622M | 557M | 557M |
| CapEx/OCF | N/A | 14.9% | 24.5% | 21.6% | 21.6% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 766M | 1.6B | 1.6B | 1.6B |
| Dividend Yield | N/A | 2.2% | 4.2% | 4.1% | 4.7% |
| Share Buybacks | 0 | 0 | 235M | 197M | 197M |
| Buyback Yield | 0.0% | N/A | 0.6% | 0.6% | 0.6% |
| Stock-Based Comp | 141M | 137M | 254M | 136M | 136M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | 6.1B | 8.0B | 7.9B | 8.9B |
| Cash & Equiv. | N/A | 1.4B | 1.1B | 1.1B | 1.1B |
| Long-Term Debt | N/A | 7.7B | 7.1B | 7.1B | 7.1B |
| Debt/Equity | N/A | 0.79 | 1.05 | 0.93 | 0.93 |
| Interest Coverage | N/A | 10.7 | 4.9 | 6.4 | 6.4 |
| Equity | N/A | 11.2B | 9.7B | 10.8B | 10.8B |
| Total Assets | N/A | 27.9B | 25.6B | 27.1B | 27.1B |
| Total Liabilities | N/A | 16.6B | 15.9B | 16.3B | 16.3B |
| Intangibles | 9.1B | 9.6B | 8.5B | 8.7B | 8.7B |
| Retained Earnings | N/A | 429M | -93M | -204M | -204M |
| Working Capital | N/A | 657M | -214M | -248M | -248M |
| Current Assets | N/A | 6.1B | 5.5B | 5.7B | 5.7B |
| Current Liabilities | N/A | 5.5B | 5.7B | 5.9B | 5.9B |
| Per Share Data | |||||
| EPS | 1.21 | 1.20 | 0.54 | 0.76 | 0.76 |
| Owner EPS | -0.31 | 1.01 | 0.47 | 0.78 | 0.78 |
| Book Value | N/A | 6.52 | 5.07 | 5.57 | 5.57 |
| Cash Flow/Share | 0.19 | 1.47 | 0.93 | 1.14 | 1.05 |
| Dividends/Share | 0.00 | 0.45 | 0.81 | 0.83 | 0.82 |
| Shares Out. | 1.7B | 1.7B | 1.9B | 1.9B | 1.9B |
| Valuation | |||||
| P/E Ratio | N/A | 16.3 | 37.8 | 22.4 | 22.7 |
| P/FCF | N/A | 15.7 | 29.2 | 19.1 | 19.4 |
| EV/EBIT | N/A | 14.9 | 25.5 | 16.9 | 17.5 |
| Price/Book | N/A | 3.0 | 4.0 | 3.1 | 3.1 |
| Price/Sales | N/A | 2.4 | 2.4 | 2.5 | 2.2 |
| FCF Yield | N/A | 6.4% | 3.4% | 5.2% | 5.2% |
| Market Cap | 0 | 33.7B | 39.0B | 32.9B | 33.4B |
| Avg. Price | 0.00 | 20.43 | 19.37 | 19.73 | 17.26 |
| Year-End Price | 0.00 | 19.60 | 20.44 | 16.99 | 17.26 |
Kenvue Inc. passes 5 of 9 quality checks, suggesting mixed fundamentals.
Kenvue Inc. trades at 22.7x trailing earnings, compared to its 15-year median P/E of 22.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 19.2x vs a median of 19.1x. The company's 5-year average ROIC is 9.8% with a gross margin of 56.9%. Total shareholder yield (dividends + buybacks) is 5.3%. At current prices, the estimated annualized return to fair value is -8.1%.
Kenvue Inc. (KVUE) has a current P/E ratio of 22.7, compared to its historical median P/E of 22.4. The stock is currently considered Fair based on its historical valuation range.
Kenvue Inc. (KVUE) has a 5-year average return on invested capital (ROIC) of 9.8%. This is below average and may indicate limited pricing power.
Kenvue Inc. (KVUE) has a market capitalization of $33.4B. It is classified as a large-cap stock.
Yes, Kenvue Inc. (KVUE) pays a dividend with a trailing twelve-month yield of 4.74%. The company also returns capital through share buybacks, with a buyback yield of 0.59%.
Based on historical P/E analysis, Kenvue Inc. (KVUE) appears fair. The current P/E of 22.7 is 2% above its historical median of 22.4. The estimated fair value CAGR (P/E method) is -13.3%.
Kenvue Inc. (KVUE) operates in the Perfumes, Cosmetics & Other Toilet Preparations industry, within the Consumer Defensive sector.
Kenvue Inc. (KVUE) reported annual revenue of $15.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
Kenvue Inc. (KVUE) has a net profit margin of 9.7%. This is a modest margin.
Kenvue Inc. (KVUE) generated $1.7 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Kenvue Inc. (KVUE) has a debt-to-equity ratio of 0.93. This indicates moderate leverage.
Kenvue Inc. (KVUE) reported earnings per share (EPS) of $0.76 in its most recent fiscal year.
Kenvue Inc. (KVUE) has a return on equity (ROE) of 14.4%. This indicates moderate shareholder returns.
Kenvue Inc. (KVUE) has a 5-year average gross margin of 56.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 4 years of financial data for Kenvue Inc. (KVUE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kenvue Inc. (KVUE) has a book value per share of $5.57, based on its most recent annual SEC filing.